WallStreetZenWallStreetZen

NASDAQ: MNPR
Monopar Therapeutics Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MNPR

Based on 4 analysts offering 12 month price targets for Monopar Therapeutics

Min Forecast
$40.00-15.34%
Avg Forecast
$62.50+32.28%
Max Forecast
$76.00+60.85%

Should I buy or sell MNPR stock?

Based on 4 analysts offering ratings for Monopar Therapeutics.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MNPR's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MNPR as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their MNPR stock forecasts and price targets.

MNPR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-07
lockedlocked$00.00+00.00%2025-06-23
lockedlocked$00.00+00.00%2025-04-01
lockedlocked$00.00+00.00%2025-03-19

1 of 1

Forecast return on equity

Is MNPR forecast to generate an efficient return?

Company
44.79%
Industry
171.33%
Market
90.85%
MNPR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MNPR forecast to generate an efficient return on assets?

Company
43.57%
Industry
46.24%
MNPR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MNPR earnings per share forecast

What is MNPR's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.88
Avg 2 year Forecast
-$3.41
Avg 3 year Forecast
$0.66

MNPR revenue forecast

What is MNPR's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$4.6M
Avg 2 year Forecast
$43.2M
Avg 3 year Forecast
$79.7M

MNPR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MNPR$47.25$62.50+32.28%Strong Buy
VNDA$4.86$16.50+239.51%Strong Buy
OCGN$1.00$7.00+600.00%Strong Buy
SLN$6.22$32.60+424.12%Buy
MREO$1.78$6.33+255.79%Strong Buy
View Top Biotech Stocks

Monopar Therapeutics Stock Forecast FAQ

Is Monopar Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: MNPR) stock is to Strong Buy MNPR stock.

Out of 4 analysts, 3 (75%) are recommending MNPR as a Strong Buy, 1 (25%) are recommending MNPR as a Buy, 0 (0%) are recommending MNPR as a Hold, 0 (0%) are recommending MNPR as a Sell, and 0 (0%) are recommending MNPR as a Strong Sell.

If you're new to stock investing, here's how to buy Monopar Therapeutics stock.

What is MNPR's earnings growth forecast for 2025-2027?

(NASDAQ: MNPR) Monopar Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.89%.

Monopar Therapeutics's earnings in 2025 is -$16,570,165.On average, 5 Wall Street analysts forecast MNPR's earnings for 2025 to be -$11,496,602, with the lowest MNPR earnings forecast at -$15,471,491, and the highest MNPR earnings forecast at -$7,949,778. On average, 4 Wall Street analysts forecast MNPR's earnings for 2026 to be -$20,868,168, with the lowest MNPR earnings forecast at -$36,752,436, and the highest MNPR earnings forecast at -$10,273,560.

In 2027, MNPR is forecast to generate $4,036,041 in earnings, with the lowest earnings forecast at $3,669,128 and the highest earnings forecast at $4,402,954.

What is MNPR's revenue growth forecast for 2026-2028?

(NASDAQ: MNPR) Monopar Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.67%.

Monopar Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast MNPR's revenue for 2026 to be $28,160,560, with the lowest MNPR revenue forecast at $23,237,813, and the highest MNPR revenue forecast at $33,083,308. On average, 2 Wall Street analysts forecast MNPR's revenue for 2027 to be $263,993,788, with the lowest MNPR revenue forecast at $256,227,467, and the highest MNPR revenue forecast at $271,760,110.

In 2028, MNPR is forecast to generate $487,137,947 in revenue, with the lowest revenue forecast at $472,828,346 and the highest revenue forecast at $501,447,548.

What is MNPR's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MNPR) forecast ROA is 43.57%, which is lower than the forecast US Biotechnology industry average of 46.24%.

What is MNPR's Price Target?

According to 4 Wall Street analysts that have issued a 1 year MNPR price target, the average MNPR price target is $62.50, with the highest MNPR stock price forecast at $76.00 and the lowest MNPR stock price forecast at $40.00.

On average, Wall Street analysts predict that Monopar Therapeutics's share price could reach $62.50 by Jul 7, 2026. The average Monopar Therapeutics stock price prediction forecasts a potential upside of 32.28% from the current MNPR share price of $47.25.

What is MNPR's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MNPR) Monopar Therapeutics's current Earnings Per Share (EPS) is -$4.00. On average, analysts forecast that MNPR's EPS will be -$1.88 for 2025, with the lowest EPS forecast at -$2.53, and the highest EPS forecast at -$1.30. On average, analysts forecast that MNPR's EPS will be -$3.41 for 2026, with the lowest EPS forecast at -$6.01, and the highest EPS forecast at -$1.68. In 2027, MNPR's EPS is forecast to hit $0.66 (min: $0.60, max: $0.72).

What is MNPR's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MNPR) forecast ROE is 44.79%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.